Prochlorperazine Mesilate
Indications
Prochlorperazine Mesilate is used for:
Vertigo, Psychoses, Nausea and vomiting, Severe anxiety disorders
Adult Dose
IV/IM:
Nausea and vomiting
Adult: As mesilate: 12.5 mg by deep IM. If required, may give further doses via oral admin.
Psychoses
Adult: As mesilate: 12.5-25 mg by deep IM Inj bid/tid.
Oral
Prophylaxis of nausea and vomitting
Adult: As mesilate: 5-10 mg bid/tid. May also be given rectally.
Nausea and vomiting
Adult: As mesilate: 20 mg, further doses are given if needed. Recommended buccal dose: As maleate: 3-6 mg bid.
Psychoses
Adult: As mesilate: 12.5 mg bid for 7 days, adjusted gradually to 75-100 mg daily according to response. Usual maintenance dose: 25-50 mg daily.
Adjunct in severe anxiety disorders
Adult: As mesilate: 5-10 mg, up to 3-4 times daily.
Vertigo
Adult: As mesilate: 15-30 mg daily, given in divided doses. May reduce gradually to 5-10 mg daily. Recommended buccal dose: 3-6 mg bid.
Child Dose
Psychoses
Child: 1-5 yr: 1.25-2.5 mg;
5-12 yr: 2.5-5 mg.
May be given up to tid, if necessary.
Renal Dose
Administration
May be taken with or without food.
Contra Indications
CNS depression, comatose patients. Bone marrow depression, phaechromocytoma, prolactin-dependent tumours, hypersensitivity. Childn <2 yr. Pregnancy and lactation.
Precautions
Extrapyramidal syndrome, hypotension, epilepsy, impaired hepatic, renal, CV, cerebrovascular or respiratory function, glaucoma. May impair ability to drive or perform tasks requiring mental alertness or physical coordination. Parenteral use in children is not recommended. History of jaundice, parkinsonism, diabetes mellitus, hypothyroidism, myasthenia gravis, paralytic ileus, prostatic hyperplasia or urinary retention. Regular eye examinations are recommended in patients on long-term treatment.
Lactation: Phenothiazines may be excreted in breast milk; do not nurse
Pregnancy-Lactation
Pregnancy category: C
Lactation: Phenothiazines may be excreted in breast milk; do not nurse
Interactions
Additive anticholinergic effects with antihistamines, tricyclic antidepressants and drugs used in parkinsonism. May reduce the antihypertensive effect of guanethidine and other adrenergic neurone blockers. May also increase risk of arrhythmias when used with drugs that prolong QT interval.
Potentially Fatal: Potentiation of other CNS depressants including alcohol, sedatives, hypnotics, barbiturates, opioids, antihistamines and general anaesthetics.
Adverse Effects
Side effects of Prochlorperazine Mesilate :
<1%
Insomnia, Restlessness, Dizziness, Anxiety, Euphoria, Agitation, Depression, Weakness, Headache, Cerebral edema, Poikilothermia, Tachycardia, ECG changes, Anorexia, Dyspepsia, Constipation, Diarrhea, Ileus, Blood dyscrasia, Galactorrhea, Gynecomastia, Ejaculatory disorder, Lens opacities (with prolonged use), Photosensitivity, Pruritus
Frequency Not Defined
Akathisia, Sedation, Anticholinergic effects, Weight gain, Oligomenorrhea or amenorrhea, Erectile dysfunction, Extrapyramidal symptoms (muscle stiffness, dystonia, parkinsonism, tardive dyskinesia), Neuroleptic malignant syndrome (infrequent but serious), Seizure, Decreased gag reflex, Confusion, Hypotension, Hypertension, Leukopenia, Agranulocytosis, Cholestatic jaundice, Photosensitivity reaction, Priapism, Hepatotoxicity
Potentially Fatal: Bone-marrow suppression. Cardiac arrhythmias or aspiration.
Potentially Fatal: Bone-marrow suppression. Cardiac arrhythmias or aspiration.
Mechanism of Action
Antiemetic: Antidopaminergic effect, blocking dopamine receptors in the brain, blocking vagus nerve in GI tract.
Antipsychotic: Blocking mesolimbic dopamine receptors, and blocking alpha-adrenergic receptors (D1 and D2) in brain.